Jim Cramer's Mad Dash: Gilead Sciences Still Has Upside

NEW YORK (TheStreet) -- Gilead Sciences (GILD) crushed analysts' bottom line expectations while also beating on revenue estimates, which grew 136% year-over-over. 

This stock sells at just nine times forward estimates, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, argued on CNBC's "Cramer's Mad Dash" segment. 

The company's drug, Sovaldi, is a cure for hepatitis C, and could go on to be the largest drug of all time, co-host David Faber added. 

Sales for the drug will likely run higher than the suggested $10 billion annual run-rate, Cramer said. 

The company was "very humble" about its results -- perhaps too humble -- and should continue to see long-term growth, as many future patients do not yet realize they have hep. C, Cramer concluded. 

-- Written by Bret Kenwell in Petoskey, Mich.

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

More from Opinion

AAP Exclusive: Cramer Says The President is No Longer on the Side of the Bulls

AAP Exclusive: Cramer Says The President is No Longer on the Side of the Bulls

Why It Makes Perfect Sense for Netflix and Amazon to Buy Up Movie Theaters

Why It Makes Perfect Sense for Netflix and Amazon to Buy Up Movie Theaters

2 More Reasons to Sell All Your Stocks and Run Away

2 More Reasons to Sell All Your Stocks and Run Away

Sean Hannity's Link to Trump Lawyer Raises Questions: Doug Kass Insider

Sean Hannity's Link to Trump Lawyer Raises Questions: Doug Kass Insider

Netflix Blowout Earnings Remind Investors of One Thing: This Company Is a Beast

Netflix Blowout Earnings Remind Investors of One Thing: This Company Is a Beast